Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon CancerChristine Ribic, Steven Gallinger, Daniel J. Sargent et al.|New England Journal of Medicine|2003Cited by 2.1k
A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly PatientsDaniel J. Sargent, Guido Francini|New England Journal of Medicine|2001Cited by 992
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)Axel Grothey, Mark Kozloff, Mary M. Sugrue et al.|Journal of Clinical Oncology|2008Cited by 695
Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II StudySteven R. Alberts, John H. Donohue, William L. Horvath et al.|Journal of Clinical Oncology|2005Cited by 541
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant TherapyFrank A. Sinicrope, Daniel J. Sargent, Silvia Marsoni et al.|JNCI Journal of the National Cancer Institute|2011Cited by 527